Are Research Peptides Legal in Australia? 2026 Guide

Research peptides occupy a specific regulatory space in Australia. Many peptides are not individually scheduled under the Therapeutic Goods Administration (TGA) Poisons Standard when supplied for legitimate research use rather than therapeutic use. However, the regulatory picture is compound-specific, use-dependent, and jurisdiction-dependent, and it has evolved in recent years.

The key principle is the distinction between therapeutic supply (supplying a product for use in or on humans or animals to prevent, diagnose, or treat a condition) and research supply (supplying a compound for in-vitro laboratory or scientific research purposes, not for administration). These are treated differently under Australian law.

The Therapeutic Goods Administration (TGA) regulates substances through the Poisons Standard (the Standard for the Uniform Scheduling of Medicines and Poisons, or SUSMP). The scheduling system categorises substances into schedules based on their risk profile:

• Schedule 2 (S2), pharmacy medicines, lower risk
• Schedule 3 (S3), pharmacist-only medicines
• Schedule 4 (S4), prescription-only medicines (the most common category for peptide hormones with approved therapeutic uses)
• Schedule 8 (S8), controlled drugs (narcotics, certain anabolic agents)
• Schedule 9 (S9), prohibited substances

Peptides that have approved therapeutic uses in Australia (such as HGH (somatotropin), semaglutide, or certain GHRH analogues) are typically Schedule 4. This means therapeutic supply requires a prescription. However, scheduling applies to therapeutic use; the same substance supplied for laboratory research purposes is not automatically covered by the same restrictions.

When a supplier sells peptides as "research use only" or "not for human consumption," this reflects a genuine legal distinction, not simply a disclaimer. Research-grade compounds supplied for in-vitro laboratory use (cell cultures, assays, non-clinical studies) are not regulated as therapeutic goods under the Therapeutic Goods Act 1989 in the same way as medicines intended for therapeutic application.

Key conditions that define legitimate research supply:

• The compound is supplied and used for scientific investigation, not for administration to humans or animals
• The supplier does not make therapeutic claims
• The purchaser is conducting legitimate laboratory or scientific research
• The supply chain and end use are consistent with research rather than therapeutic application

This framework is how research chemicals have long been supplied to universities, pharmaceutical laboratories, and independent researchers globally.

Many peptides commonly researched in Australia are not individually scheduled under the Poisons Standard when not supplied for therapeutic use. These include:

• BPC-157 (body protection compound), not a scheduled substance; widely available for research
• TB-500 (Thymosin Beta-4 fragment), not individually scheduled for research supply
• Selank and Semax, nootropic peptides not individually scheduled
• Epitalon (Epithalan tetrapeptide), not individually scheduled
• GHK-Cu, copper peptide, widely used in research contexts
• MOTS-c and SS-31, mitochondrial peptides not individually scheduled

Peptides with existing TGA-approved therapeutic applications (HGH, semaglutide, tirzepatide) carry S4 scheduling for therapeutic supply, but are still studied in research contexts under appropriate conditions.

Separate from TGA scheduling, many peptides appear on the WADA (World Anti-Doping Agency) Prohibited List and are banned in competitive sport by ASADA (Australian Sports Anti-Doping Authority). This is a separate regulatory framework from TGA scheduling and applies specifically to competitive athletes subject to anti-doping rules.

The WADA Prohibited List bans many peptide hormones, growth factors, and related substances (including GH, IGF-1, GHRPs (like Ipamorelin), and GHRH analogues) for use in sport regardless of whether they are prescribed or supplied for research. Researchers who are competitive athletes should be aware of this distinction.

ASADA prohibition and TGA scheduling are independent frameworks. A substance can be: (a) not TGA-scheduled but WADA-prohibited; (b) TGA S4 and WADA-prohibited; or (c) neither. Researchers should check both frameworks relevant to their circumstances.

While the TGA operates at the Commonwealth level, state and territory health legislation can apply additional restrictions to scheduling and supply. The Poisons Standard is generally adopted by all states and territories via their own poisons legislation, but implementation details can vary.

Researchers in all Australian states and territories should ensure their activities comply with both Commonwealth (TGA) and relevant state/territory legislation. This is particularly relevant for peptides with therapeutic applications, where state pharmacy and medicines legislation may apply.

OzPeps supplies research-grade peptides and compounds strictly for in-vitro laboratory and scientific research use, not for human or animal administration. All compounds are sold with research-use-only labelling, and OzPeps does not make therapeutic claims about any product.

Products are sourced from suppliers with verified supplier Certificate of Analysis (COA) confirming identity and purity. OzPeps operates within the research compound supply framework and does not facilitate therapeutic supply of scheduled medicines.

Purchasers must be 18 years of age or older, must acknowledge research-use-only terms at purchase, and are solely responsible for compliance with all applicable laws and regulations in their jurisdiction. If in doubt about the regulatory status of a specific compound for your intended use, consult a legal or regulatory professional.

For information on specific research compounds available in Australia:

• BPC-157 Research Guide →
• Epitalon (Epithalan) Research Guide →
• Longevity Peptides in Australia →
• Semax Research Guide →